Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Thalidomide treatment proves better than conventional chemotherapy for multiple myeloma

21.06.2005


When people hear "thalidomide," many think "birth defects," however, evidence has come to light that this once-banned drug can be used as a potent anti-cancer treatment. In a new study, researchers from the University of Bologna, Italy, demonstrate that Thal-Dex (thalidomide used in combination with dexamethasone) is more powerful than conventional chemotherapy for the treatment of multiple myeloma. Their findings will be published in the July 1, 2005, issue of Blood, the official journal of the American Society of Hematology.
Each year, approximately 15,000 Americans are diagnosed with multiple myeloma, an incurable and painful disease of the bone marrow. Most patients who receive this diagnosis have less than five years to live; however, many can undergo autologous (self-donor) stem cell transplants to help prolong survival. Although thalidomide has been studied for the treatment of advanced stages of multiple myeloma since the late 1990s, this is the first large study to compare its effectiveness to standard drugs as part of front-line therapy with stem cell transplantation.

Because the odds for a successful transplant increase as the number of cancer cells decreases, patients receive chemotherapy a few months before the procedure. In this study, 100 multiple myeloma patients given Thal-Dex before transplant were compared to 100 patients given traditional chemotherapy with VAD (a combination of three drugs: vincristine, adriamycin, and dexamethasone).


Thal-Dex patients were more likely to have successful results; 76 percent received at least a partial remission. Of the VAD patients, only 52 percent had a positive response to treatment, meaning that nearly half had either no response, or a progression of their disease. Patients taking Thal-Dex also had a more profound reduction in the size of their tumors.

Not only was Thal-Dex a more effective treatment, but its two-pill regimen is also greatly preferred by patients over intravenous VAD treatments. A vital consideration for patients undergoing autologous stem cell transplant is that toxicity from chemotherapy not impair the collection of stem cells needed for the transplant. In that respect, patients in both the Thal-Dex and the VAD group were able to collect enough healthy stem cells for transplantation and there was no significant difference between the two.

main side effect of Thal-Dex was deep vein thrombosis, which 15 percent of patients on the drug experienced. Although this effect was treated successfully with anti-coagulants, researchers speculate that further research needs to be done to help predict which patients will experience this outcome in order to find ways to make treatment with Thal-Dex safer for them. The main side effect of VAD was granulocytopenia (low white blood cell levels), which was severe in 12 percent of the patients in that group.

"It’s time to look at thalidomide in a new light," said Michele Cavo, M.D., professor at the University of Bologna and lead study author. "It’s earned its place in modern medicine. Thalidomide has proven to be a highly effective, relatively safe, and more comfortable treatment for patients with multiple myeloma than traditional chemotherapy."

This work was supported by grants from the University of Bologna, the Ministero dell’Università e Ricerca Scientifica, and the Carisbo Foundation.

Laura Stark | EurekAlert!
Further information:
http://www.hematology.org
http://www.bloodjournal.org

More articles from Studies and Analyses:

nachricht New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg

nachricht Disarray in the brain
18.12.2017 | Universität zu Lübeck

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Novel 3-D printing technique yields high-performance composites

16.01.2018 | Materials Sciences

New application for acoustics helps estimate marine life populations

16.01.2018 | Life Sciences

Fast-tracking T cell therapies with immune-mimicking biomaterials

16.01.2018 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>